In the treatment of inflammatory bowel disease, synthetic mucus gels can be used to deliver monoclonal antibodies without inducing broad immunosuppression.
In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...
Allergic diseases represent a major global health burden, placing significant strain on health care systems worldwide. Severe ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...
Genentech's native HIC-MS method uses ammonium tartrate, enabling efficient MS detection without compromising chromatographic ...
5don MSN
OHSU researchers identify key trigger behind brain disorder often mistaken for mental illness
Some serious brain disorders begin with symptoms that are easy to misinterpret. A person may become confused, forgetful or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results